ABSTRACT
Infergen should be administered subcutaneously three times a week for a period of 12 months. Infergen was found to be as effective as interferon alfa -2b in the treatment of chronic hepatitis. The side effects reported after use of Infergen are similar to those observed after administration of other interferons, including flu-like symptoms. Cardiovascular and psychiatric disorders have occasionally been reported, as well as the development of neutralizing anti-interferon antibodies in 4% of patients. Infergen is contraindicated during pregnancy and lactation and in the case of severe psychiatric, cardiovascular, renal, and hepatic disorders.
